Claims for Patent: 5,972,917

Summary for Patent: 5,972,917

Title:	1 .alpha.-hydroxy-25-ene-vitamin D, analogs and uses thereof
Abstract:	The invention provides 1.alpha.-hydroxyvitamin D compounds in which the C-25 or equivalent position of the C-17 side chain has a double bond and method for their use in the treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders.
Inventor(s):	Bishop; Charles W. (Madison, WI), Knutson; Joyce C. (Madison, WI), Strugnell; Stephen (Madison, WI)
Assignee:
Application Number:	09/087,439
Patent Claims:	1. A method of achieving an effect in a patient comprising administering an effective amount of a vitamin D compound which is represented by formula (I): wherein the effect is treating or preventing bone loss or bone mineral content, hyperparathyroidism, cellular hyperproliferation, or modulating immune and inflammatory response or inflammatory response, and wherein D is D.sup.1, D.sup.2 or D.sup.3 moiety in which D.sup.1 is a 1.alpha.-hydroxyvitamin D moiety, D.sup.2 is a 1.alpha.-hydroxyprevitamin D moiety and D.sup.3 is a 1.alpha.-hydroxycholesterol moiety or a 1.alpha.-hydroxyergosterol moiety and Z is a C-17 side chain which is a saturated or unsaturated, substituted or unsubstituted, straight-chain or branched C.sub.4 -C.sub.8 hydrocarbon group in which the C-24 or equivalent position is bonded by a single C--C bond to a lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl, and in which the C-25 or equivalent position has a double bond. 2. The method of claim 1, wherein said 1.alpha.-hydroxyvitamin D compound is a compound of formula (II): ##STR13## wherein Y is a methylene group if the bond to Y is a double bond or a methyl group or hydrogen if the bond to Y is a single bond; and X is hydrogen, lower alkyl or lower fluoroalkyl. 3. The method according to claim 2, wherein said 1.alpha.-hydroxyvitamin D compound is 1.alpha.-hydroxy-25-ene-D.sub.2 ; 1.alpha.-hydroxy-25-ene-D.sub.4 ; 1.alpha.-hydroxy-25-oxo-D.sub.2 ; or 1.alpha.-hydroxy-25-oxo-D.sub.4. 4. The method of claim 1, wherein said 1.alpha.-hydroxyvitamin D is a compound of formula (IIA): ##STR14## wherein Y is a methylene group if the bond to Y is a double bond or is a methyl group or hydrogen if the bond to Y is a single bond; and X is hydrogen, lower alkyl or lower fluoroalkyl. 5. The method of claim 1, wherein said 1.alpha.-hydroxyprevitamin D compound is a compound of formula (III): ##STR15## wherein X is hydrogen, lower alkyl or lower fluoroalkyl; and Y is hydrogen or a methyl group. 6. The method of claim 1, wherein Z is a side chain represented by formula (VA): ##STR16## wherein n is an integer which is 1 or 2; R.sup.3 is hydrogen, lower alkyl, lower fluoroalkyl, lower alkenyl and lower fluoroalkenyl; R.sup.4 and R.sup.5 are independently lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; A is carbon, oxygen, sulfur or nitrogen; r and s are 1 when A is carbon; r is 1 and s is zero when A is nitrogen; r and s are zero where A is oxygen or sulfur; and R.sup.6 and R.sup.7 are independently hydrogen, lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl. 7. The method of claim 1, wherein Z is a side chain represented by formula (VC): ##STR17## wherein a dotted line along the side chain represents an optional additional C--C bond; q is zero or an integer which is 1 or 2; R.sup.3 is hydrogen, lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; R.sup.4 and R.sup.5 are independently lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; A is carbon, oxygen, sulfur or nitrogen; r is 1 and s is zero when A is nitrogen; r and s are 1 when A is carbon; r and s are zero when A is sulfur or oxygen; and R.sup.6 and R.sup.7 independently are hydrogen, lower alkyl, lower alkenyl, lower fluoroalkyl or lower fluoroalkenyl. 8. A method of achieving an effect in a patient comprising administering an effective amount of a vitamin D compound which is represented by formula (I): wherein the effect is increasing or maintaining bone mass or bone mineral content, lowering or maintaining lowered parathyroid hormone level, inhibiting hyperproliferative effects, inducing or enhancing cell differentiation modulating immune response, and modulating inflammatory response, and wherein D is D.sup.1, D.sup.2 or D.sup.3 moiety in which D.sup.1 is a 1.alpha.-hydroxyvitamin D moiety, D.sup.2 is a 1.alpha.-hydroxyprevitamin D moiety and D.sup.3 is a 1.alpha.-hydroxycholesterol moiety or a 1.alpha.-hydroxyergosterol moiety and Z is a C-17 side chain which is a saturated or unsaturated, substituted or unsubstituted, straight-chain or branched C.sub.4 -C.sub.18 hydrocarbon group in which the C-24 or equivalent position is bonded by a single C--C bond to a lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl, and in which the C-25 or equivalent position has a double bond. 9. The method of claim 8, wherein said vitamin D compound is a compound of formula (II): ##STR18## or of formula (III): ##STR19## wherein X is a hydrogen, lower alkyl or lower fluoroalkyl; and Y is a methylene group if the bond to Y is a double bond or is a methyl group or hydrogen if the bond to Y is a single bond; and wherein Z is a side chain of formula (VA): ##STR20## wherein n is an integer which is 1 or 2; R.sup.3 is hydrogen, lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; R.sup.4 and R.sup.5 are independently lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; A is carbon, oxygen, sulfur or nitrogen; r is 1 and s is zero when A is nitrogen; r and s are 1 when A is carbon; r and s are zero when A is sulfur or oxygen; and R.sup.6 and R.sup.7 are independently hydrogen, lower alkyl, lower alkenyl, lower fluoroalkyl or lower fluoroalkenyl; or of formula (VC): ##STR21## wherein a dotted line along the side chain represents an optional additional C--C bond; q is zero or an integer which is 1 or 2; R.sup.3 is hydrogen, lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; R.sup.4 and R.sup.5 are independently lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; A is carbon, oxygen, sulfur or nitrogen; r is 1 and s is zero when A is nitrogen; r and s are 1 when A is carbon; r and s are zero when A is sulfur or oxygen; and R.sup.6 and R.sup.7 are independently hydrogen, lower alkyl, lower alkenyl, lower fluoroalkyl or lower fluoroalkenyl. 10. A method of treating a human to alleviate the pathological effects of osteoporosis, hyperparathyroidism, psoriasis, skin cancer, breast cancer, colon cancer, prostate cancer, prostatic hyperplasia and impaired immune response, wherein the method comprises administering to the human a vitamin D compound which is represented by formula (I): wherein the effect is treating or preventing bone loss or bone mineral content, hyperparathyroidism, cellular hyperproliferation, or modulating immune and inflammatory response or inflammatory response, wherein D is D.sup.1, D.sup.2 or D.sup.3 moiety in which D.sup.1 is a 1.alpha.-hydroxyvitamin D moiety, D.sup.2 is a 1.alpha.-hydroxyprevitamin D moiety and D.sup.3 is a 1.alpha.-hydroxycholesterol moiety or a 1.alpha.-hydroxyergosterol moiety and Z is a C-1 7 side chain which is a saturated or unsaturated, substituted or unsubstituted, straight-chain or branched C.sub.4 -C.sub.18 hydrocarbon group in which the C-24 or equivalent position is bonded by a single C--C bond to a lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl, and in which the C-25 or equivalent position has a double bond. 11. A pharmaceutical composition comprising an effective amount of a 1.alpha.-hydroxyvitamin D compound which is represented by formula (I): wherein the effect is treating or preventing bone loss or bone mineral content, hyperparathyroidism, cellular hyperproliferation, or modulating immune and inflammatory response or inflammatory response, wherein D is D.sup.1, D.sup.2 or D.sup.3 moiety in which D.sup.1 is a 1.alpha.-hydroxyvitamin D moiety, D.sup.2 is a 1.alpha.-hydroxyprevitamin D moiety and D.sup.3 is a 1.alpha.-hydroxycholesterol moiety or a 1.alpha.-hydroxyergosterol moiety and Z is a C-17 side chain which is a saturated or unsaturated, substituted or unsubstituted, straight-chain or branched C.sub.4 -C.sub.18 hydrocarbon group in which the C-24 or equivalent position is bonded by a single C--C bond to a lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl, and in which the C-25 or equivalent position has a double bond, and a pharmaceutically acceptable carrier, adjuvant or vehicle. 12. The composition of claim 11, wherein the composition is orally administrable. 13. The composition of claim 11, wherein said vitamin D compound is presented in a dosage of 3.5 .mu.g to about 1000 .mu.g/week. 14. The method of claim 1, wherein said vitamin D compound is administered in combination with a bone agent, a cytotoxic agent, an immuno response regulating agent, an antiinflammatory agent or combinations thereof. 15. The method of claim 14, wherein said bone agent is other vitamin D compounds, conjugated estrogens, sodium fluorides, biphosphonates, cobalamin, calcium receptor agonists, pertussin toxin, boron or DHEA. 16. A 1.alpha.-hydroxyvitamin D compound which is a compound of formula (II): ##STR22## or a compound of formula (III): ##STR23## wherein Z is a C-17 side chain which is a saturated or unsaturated, substituted or unsubstituted, straight-chain or branched C.sub.4 -C.sub.18 hydrocarbon group in which the C-24 or equivalent position is bonded by a single C--C bond to a lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl, and in which the C-25 or equivalent position has a double bond; Y is a methylene group if the bond to Y is a double bond or a methyl group or hydrogen if the bond to Y is a single bond; and X is hydrogen, lower alkyl or lower fluoroalkyl. 17. The compound of claim 16, wherein Z is a side chain of formula (VA): ##STR24## wherein n is an integer which is 1 or 2; R.sup.3 is hydrogen, lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; R.sup.4 and R.sup.5 are independently lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; A is carbon, oxygen, sulfur or nitrogen; r is 1 and s is zero when A is nitrogen; r and s are 1 when A is carbon; r and s are zero when A is sulfur or oxygen; and R.sup.6 and R.sup.7 are independently hydrogen, lower alkyl, lower alkenyl, lower fluoroalkyl or lower fluoroalkenyl; or of formula (VC): ##STR25## wherein a dotted line along the side chain represents an optional additional C--C bond; q is zero or an integer which is 1 or 2; R.sup.3 is hydrogen, lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; R.sup.4 and R.sup.5 are independently lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; A is carbon, oxygen, sulfur or nitrogen; r is 1 and s is zero when A is nitrogen; r and s are 1 when A is carbon; r and s are zero when A is sulfur or oxygen; and R.sup.6 and R.sup.7 are hydrogen, lower alkyl, lower alkenyl, lower fluoroalkyl or lower fluoroalkenyl. 18. A 1.alpha.,24-dihydroxyvitamin D compound which is a compound of formula (II): ##STR26## or a compound of formula (III): ##STR27## or a compound of formula (IV): ##STR28## wherein Z is a side chain of formula (VE): ##STR29## wherein n is an integer which is 1 or 2; R.sup.3 is hydrogen, lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; R.sup.4 and R.sup.5 are independently lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; A is carbon, oxygen, sulfur or nitrogen; r is 1 and s is zero when A is nitrogen; r and s are 1 when A is carbon; r and s are zero when A is sulfur or oxygen; and R.sup.6 and R.sup.7 are hydrogen, lower alkyl, lower alkenyl, lower fluoroalkyl or lower fluoroalkenyl; or of formula (VF): ##STR30## wherein q is zero or an integer which is 1 or 2; R.sup.3 is hydrogen, lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; R.sup.4 and R.sup.5 are independently lower alkyl, lower fluoroalkyl, lower alkenyl or lower fluoroalkenyl; A is carbon, oxygen, sulfur or nitrogen; r is 1 and s is zero when A is nitrogen; r and s are 1 when A is carbon; r and s are zero when A is sulfur or oxygen; R.sup.6 and R.sup.7 independently are hydrogen, lower alkyl, lower alkenyl, lower fluoroalkyl or lower fluoroalkenyl. 19. The compound of claim 18, wherein Z is a side chain of formula (VG): ##STR31## or of formula (VH): ##STR32##

Details for Patent 5,972,917

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26